MarketPulse

allogeneic hematopoietic cell transplantation

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Posts $28.7M Q1 Loss as Pipeline Advances Toward Phase 3

TScan Therapeutics reports $28.7M Q1 loss, $1.0M revenue; $128.1M cash funds operations to H2 2027 amid Phase 3 pipeline advancement.
TCRXclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Seres Therapeutics Demonstrates SER-155 Promise in Transplant Patients at ESCMID

Seres Therapeutics presented Phase 1b data for SER-155 showing microbiome shifts and reduced infections in transplant patients at ESCMID Global 2026.
MCRBallogeneic hematopoietic cell transplantationPhase 1b trial
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Advances TCR Cell Therapy Pipeline With FDA Clearance, Conference Participation

TScan Therapeutics secures FDA clearance for two IND applications and completes Phase 1 trial enrollment using commercial-scale manufacturing, advancing its TCR cell therapy pipeline.
TCRXclinical-stage biotechsolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Na

TScan Advances Allogeneic Cell Therapy Pipeline With FDA IND Clearances and Trial Enrollment Milestones

TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.
TCRXclinical trialTCR-T therapy